Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Subacute cutaneous lupus erythematosus induced by nivolumab.

× No keyword cloud information.

11 in total

Review 1. The relationships between cancer and autoimmune rheumatic diseases.

Authors: Laura C Cappelli; Ami A Shah
Journal: Best Pract Res Clin Rheumatol Date: 2020-02-03 Impact factor: 4.098

2. Nivolumab-Induced de novo Discoid Lupus Erythematosus.

Authors: Jaya Manjunath; Mark Mochel; Fnu Nutan
Journal: Case Rep Dermatol Date: 2022-04-21

Review 3. Cutaneous Lupus Erythematosus: Progress and Challenges.

Authors: Amy J Petty; Lauren Floyd; Christopher Henderson; Matilda W Nicholas
Journal: Curr Allergy Asthma Rep Date: 2020-04-04 Impact factor: 4.806

Review 4. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.

Authors: Laura C Cappelli; Clifton O Bingham
Journal: Arthritis Rheumatol Date: 2021-03-05 Impact factor: 10.995

Review 5. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.

Authors: Devis Benfaremo; Lucia Manfredi; Michele Maria Luchetti; Armando Gabrielli
Journal: Curr Drug Saf Date: 2018

6. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.

Authors: Marie Kostine; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal: Rheumatology (Oxford) Date: 2019-12-01 Impact factor: 7.580

7. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors: Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal: Rheumatology (Oxford) Date: 2019-12-01 Impact factor: 7.580

8. Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.

Authors: Isabella Pospischil; Wolfram Hoetzenecker
Journal: J Dtsch Dermatol Ges Date: 2021-11 Impact factor: 5.231

9. Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus.

Authors: Zsófia Király; Ágota Szepesi; Anna Sebestyén; Enikő Kuroli; Fanni Rencz; Béla Tóth; Laura Bokor; József Szakonyi; Márta Medvecz; Bernadett Hidvégi
Journal: Pathol Oncol Res Date: 2022-08-01 Impact factor: 2.874

10. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review.

Authors: Nathathai Pratumchart; Kumutnart Chanprapaph; Nuttapong Topibulpong; Jutamas Tankunakorn
Journal: Clin Cosmet Investig Dermatol Date: 2022-01-13